VBP15 For Treating Duchenne
Eric Hoffman, PhD, president and chief executive officer of Reveragen, he describes the four subactivities in detail that should make VBP15 a more suitable glucocorticicoid for boys with Duchenne muscular dystrophy.
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Eric Hoffman, PhD, president and chief executive officer of Reveragen, he describes the four subactivities in detail that should make VBP15 a more suitable glucocorticicoid for boys with Duchenne muscular dystrophy.